Back to Search
TIMOTHY MAUGHAN, MD
MD
Infectious Disease Physician
NPI: 1346282373IndividualAccepts Medicare
Specialties, Licenses & Credentials
Infectious Disease PhysicianPrimary
Internal Medicine — Infectious Disease
Code: 207RI0200X
MD00045033(WA)
CMS Specialties
PrimaryINFECTIOUS DISEASE
Education
UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE
Class of 1999
Research & Publications (20)
Management of the asymptomatic primary in the palliative treatment of metastatic colorectal cancer.
PMID 19175637·Colorectal Dis·2009
8-other
A new opportunity for radiotherapy research in the UK.
PMID 19168338·Clin Oncol (R Coll Radiol)·2009
8-other
Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience.
PMID 19165196·Br J Cancer·2009
3-trial
Cetuximab therapy in first-line metastatic colorectal cancer and intermittent palliative chemotherapy: review of the COIN trial.
PMID 18699762·Expert Rev Anticancer Ther·2008
6-review
Severe prolonged immunosuppression following fludarabine and rituximab combination therapy.
PMID 18560233·Chemotherapy·2008
5-case
Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials.
PMID 18349394·J Clin Oncol·2008
4-observational
Pancreatic cancer within a UK cancer network with special emphasis on locally advanced non-metastatic pancreatic cancer.
PMID 18346883·Clin Oncol (R Coll Radiol)·2008
8-other
Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial.
PMID 17630037·Lancet·2007
4-observational
Predicting response to epidermal growth factor receptor-targeted therapy in colorectal cancer.
PMID 17428171·Expert Rev Anticancer Ther·2007
6-review
Small cell oesophageal carcinoma: an institutional experience and review of the literature.
PMID 17299393·Br J Cancer·2007
8-other
A phase I/II study of irinotecan when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group Study.
PMID 17262086·Br J Cancer·2007
3-trial
A prospective comparison of multidisciplinary treatment of oesophageal cancer with curative intent in a UK cancer network.
PMID 17123775·Eur J Surg Oncol·2007
4-observational
Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial.
PMID 16622438·Br J Cancer·2006
3-trial
A phase I dose escalation study of continuous oral capecitabine in combination with oxaliplatin and pelvic radiation (XELOX-RT) in patients with locally advanced rectal cancer.
PMID 16284060·Ann Oncol·2006
3-trial
A phase I/II study of oxaliplatin when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group (CCOG) study.
PMID 16249791·Br J Cancer·2005
3-trial
Primary cutaneous CD30+ T-cell lymphoproliferative disorder following cardiac transplantation in a 15-year-old boy with Netherton's syndrome.
PMID 16225622·Br J Dermatol·2005
5-case
The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies.
PMID 16033478·J Dtsch Dermatol Ges·2005
4-observational
A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer.
PMID 15939714·Ann Oncol·2005
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 624 E FRONT AVE
SPOKANE, WA 99202 - Phone
- (509) 626-9904
Quick Facts
- NPI
- 1346282373
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 27
- Publications
- 20
Are you this provider?
Claim Your Profile